Company intelligence / Profile preview

Angios Biotech

Innsbruck, Tyrol, Austriaangios-bio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Angios is developing novel antibody therapeutics targeting vascular diseases with an initial focus on diabetic retinopathy. The company leverages a proprietary organoid platform to identify new pathways involved in microvascular complications. No clinical results are available yet; programs are pre-clinical.[2][3][4]

Therapeutic areas: OphthalmologyEndocrinology
Modalities: Monoclonal antibodiesBispecific antibodies[3][4]Organoid-based disease modeling[4]
Industry: Biotech

Partnerships

AbCellera Biologics Inc. – multi-year collaboration for discovery of monoclonal/bispecific antibodies against up to three targets related to diabetic eye disease.[3][4]*AbCellera receives equity, research fees, milestones & royalties.*No other major partnerships disclosed.

Beyond the preview

Go deeper on Angios Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angios Biotech.

Explore the full profile